On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. HALO secures an upfront payment, milestone payments, and royalties on commercial sales, with Incyte holding an option to nominate two additional targets. The agreement underscores a key trend in biopharma: pairing specialized delivery platforms with high-value targeted oncology pipelines.
Financial Performance & Earnings Comparison: Halozyme Therapeutics, Inc. (NASDAQ:HALO) vs. Incyte Corporation (NASDAQ:INCY)
Both companies delivered record Q2 2026 financial results, but Halozyme Therapeutics, Inc. is running at higher operational momentum.
Halozyme’s Q2 revenue jumped 48% year-over-year to $481 million, blowing past consensus estimates of ~$402 million. Non-GAAP diluted EPS reached $2.28 versus $1.79–$1.82 expected. The growth was propelled by a 50% surge in royalty revenues to $308 million, alongside aggressive capital returns via $332.8 million in share buybacks. Management raised full-year 2026 revenue guidance to $1.835–$1.910 billion and Non-GAAP EPS to $8.65–$9.00. On August 7, Wells Fargo raised its price target on HALO to $95 from $75 (Equal Weight), highlighting robust Ocrevus subQ conversion and a $1 billion mid-2030s opportunity for Hypercon, expected in clinical use by Q1 2027.
Incyte Corporation also delivered strong top-line numbers. Q2 GAAP total revenue rose 38% to $1.67 billion, with net sales climbing 40% to $1.49 billion. Non-GAAP EPS came in at $3.09. Core oncology flagship Jakafi brought in $817 million (+7% YoY), while Opzelura generated $450 million (+173% YoY), boosted by a $246 million one-time CMS settlement benefit. Incyte raised full-year net sales guidance to $5.13–$5.26 billion. While Incyte generates higher absolute revenue, Halozyme’s higher-margin royalty model yields superior operating leverage.
Bull vs. Bear Case
Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s bull case centers on its high-margin royalty structure, which supports strong free cash flow generation. The company’s expanding partnerships, including five ENHANZE/Hypercon deals signed year-to-date, along with the continued adoption of subcutaneous drug delivery, provide steady and recurring growth potential without requiring Halozyme to take on significant commercial risk. However, the bear case is that the company remains heavily reliant on a concentrated group of partner blockbuster drugs, including Ocrevus and Darzalex. Patent cliffs, regulatory setbacks, or weaker-than-expected sales of these products could therefore have a meaningful impact on Halozyme’s royalty revenue.
